In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daewoong Pharmaceutical Company Ltd.

http://www.daewoong.com/

Latest From Daewoong Pharmaceutical Company Ltd.

Korea Q1 Roundup: Overseas Sales, COVID Prove Positive In Mixed Results

Among recent highlights, SK Bioscience files for approval of recombinant protein COVID-19 vaccine GBP510, Hanmi Pharmaceutical’s Chinese subsidiary continues to report strong earnings, led by cold drug sales, while Yuhan’s novel peptide drug candidate for degenerative disc disease is set to move into a Phase III trial in the US.

South Korea Sales & Earnings

Korea’s Home-Grown New Drug Approvals Hit Record High In 2021

South Korea had a milestone year in terms of domestic new drug approvals in 2021, with multiple major pharma firms gaining nods for their in-house developed products, including the country’s first COVID-19 therapeutic, from Celltrion.

South Korea Approvals

Appetite For Korean Biotechs Turns Sour, Voronoi Withdraws IPO

Weak broader stock market sentiment, topped with negative biotech industry news, weighs on Korean bioventure IPOs in the first quarter, with unicorn Voronoi withdrawing its IPO plan. But VC financing in the sector remains steady.

South Korea Financing

Citius Aims To Use Prior Experience With CTCL Drug To Its Commercial Advantage

The company announced positive data for I/Ontak, a reformulated version of the cutaneous T-cell lymphoma drug Ontak and aims to submit for approval later in 2022.

Rare Diseases Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register